Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: A metabonomic method and its application

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Tan, Guangguo ^a,b   Lou, Ziyang ^a   Liao, Wenting ^a,b   Zhu, Zhenyu ^a,b   Dong, Xin ^a   Zhang, Wei ^a   Li, Wuhong ^a,b   Chai, Yifeng ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI KEY LABORATORY FOR PHARMACEUTICAL METABOLITE RESEARCH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; CHINESE DRUG; CREATINE KINASE; CREATINE KINASE MB; DOXORUBICIN; LACTATE DEHYDROGENASE; SINI DECOCTION; UNCLASSIFIED DRUG; HERBACEOUS AGENT; SINI TANG;

AMINO ACID METABOLISM; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CHINESE MEDICINE; CITRIC ACID CYCLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG MECHANISM; GLYCOLYSIS; HEART MUSCLE; HEART PROTECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID METABOLISM; MASS FRAGMENTOGRAPHY; METABOLITE; METABONOMIC METHOD; MOUSE; NONHUMAN; SCREENING; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; METABOLISM; METABOLOMICS; METHODOLOGY;

MUS;

ANIMALS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; DOXORUBICIN; DRUGS, CHINESE HERBAL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; METABOLOMICS; MICE; MYOCARDIUM;

EID: 81155137578     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027683     Document Type: Article

References (49)

1. Booser DJ, Hortobagyi GN, (1994) Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 47: 223-258.
2. Singal PK, Deally CM, Weinberg LE, (1987) Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 19: 817-828.
3. Singal PK, Iliskovic N, (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905.
4. Karagiannis TC, Lin AJ, Ververis K, Chang L, Tang MM, et al. (2010) Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) 2: 659-668.
5. Powis G, (1989) Free radical formation by antitumor quinones. Free Radic Biol Med 6: 63-101.
6. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, et al. (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165-167.
7. Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, et al. (1999) L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. Faseb J 13: 1501-1510.
8. Konorev EA, Kotamraju S, Zhao H, Kalivendi S, Joseph J, et al. (2002) Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. Free Radic Biol Med 33: 988.
9. Solem LE, Henry TR, Wallace KB, (1994) Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol Appl Pharmacol 129: 214-222.
10. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB, (2001) Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 61: 771-777.
11. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA, (2003) Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108: 2423-2429.
12. Sack MN, (2010) Mitochondrial Fe-S cluster biogenesis, frataxin and the modulation of susceptibility to drug-induced cardiomyopathy. Aging (Albany NY) 2: 754-755.
13. Kawasaki N, Lee JD, Shimizu H, Ishii Y, Ueda T, (1996) Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats. Int J Cardiol 55: 217-225.
14. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U, (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41: 389-405.
15. Tokarska-Schlattner M, Wallimann T, Schlattner U, (2006) Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biol 329: 657-668.
16. Gewirtz DA, (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741.
17. Zhao MQ, Wu WK, Zhao DY, Duan XF, Liu Y, (2009) Protective effects of sini decoction on adriamycin-induced heart failure and its mechanism. Zhong Yao Cai 32: 1860-1863.
18. Jin M, Qin J, Wu W, (2003) Clinical study on "sini" decoction in treating stenocardia for coronary heart disease. Zhong Yao Cai 26: 71-73.
19. Wu WK, Su JW, Lin SG, (2001) Clinical study on effect of sini decoction on ischemia/reperfusion injury by Holter monitoring in patients with acute myocardial infarction treated with thrombolytic therapy. Zhongguo Zhong Xi Yi Jie He Za Zhi 21: 744-746.
20. Zhao DY, Zhao MQ, Wu WK, (2008) Study on activity and mechanism of Sini Decoction anti-mitochondrial oxidation injury caused by myocardial ischemia/reperfusion. Zhong Yao Cai 31: 1681-1685.
21. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
22. Nicholson JK, Lindon JC, Holmes E, (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189.
23. Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, et al. (2005) Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res 19: 173-182.
24. Verpoorte R, Choi YH, Kim HK, (2005) Ethnopharmacology and systems biology: a perfect holistic match. J Ethnopharmacol 100: 53-56.
25. Park JC, Hong YS, Kim YJ, Yang JY, Kim EY, et al. (2009) A metabonomic study on the biochemical effects of doxorubicin in rats using (1)H-NMR spectroscopy. J Toxicol Environ Health A 72: 374-384.
26. Wang J, Reijmers T, Chen L, Van Der Heijden R, Wang M, et al. (2009) Systems toxicology study of doxorubicin on rats using ultra performance liquid chromatography coupled with mass spectrometry based metabolomics. Metabolomics 5: 407-418.
27. Trygg J, Holmes E, Lundstedt T, (2007) Chemometrics in metabonomics. J Proteome Res 6: 469-479.
28. Zou H, Hastie T, (2005) Regularization and variable selection via the elastic net. J R Statist Soc B 67: 301-320.
29. Kumar SN, Konorev EA, Aggarwal D, Kalyanaraman B, (2011) Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte. J Proteomics 74: 683-697.
30. Wakasugi S, Fischman AJ, Babich JW, Callahan RJ, Elmaleh DR, et al. (1993) Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med 34: 1529-1535.
31. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV, (2011) Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2: 222-233.
32. Ronen SM, DiStefano F, McCoy CL, Robertson D, Smith TA, et al. (1999) Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer 80: 1035-1041.
33. Wolf MB, Baynes JW, (2006) The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 1760: 267-271.
34. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, et al. (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112: 3868-3875.
35. Schulz TJ, Westermann D, Isken F, Voigt A, Laube B, et al. (2010) Activation of mitochondrial energy metabolism protects against cardiac failure. Aging (Albany NY) 2: 843-853.
36. Gnanapragasam A, Yogeeta S, Subhashini R, Ebenezar KK, Sathish V, et al. (2007) Adriamycin induced myocardial failure in rats: protective role of Centella asiatica. Mol Cell Biochem 294: 55-63.
37. Hong YM, Kim HS, Yoon HR, (2002) Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine. Pediatr Res 51: 249-255.
38. Bordoni A, Biagi P, Hrelia S, (1999) The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes. Biochim Biophys Acta 1440: 100-106.
39. Abdel-aleem S, el-Merzabani MM, Sayed-Ahmed M, Taylor DA, Lowe JE, (1997) Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol 29: 789-797.
40. Goormaghtigh E, Brasseur R, Ruysschaert JM, (1982) Adriamycin inactivates cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment. Biochem Biophys Res Commun 104: 314-320.
41. Todorova VK, Kaufmann Y, Hennings L, Klimberg VS, (2010) Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats. J Nutr 140: 44-48.
42. McNulty PH, Jacob R, Deckelbaum LI, Young LH, (2000) Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery disease. Metabolism 49: 1365-1369.
43. Carvalho RA, Sousa RP, Cadete VJ, Lopaschuk GD, Palmeira CM, et al. (2010) Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology 270: 92-98.
44. Wu F, Zhang EY, Zhang J, Bache RJ, Beard DA, (2008) Phosphate metabolite concentrations and ATP hydrolysis potential in normal and ischaemic hearts. J Physiol 586: 4193-4208.
45. Tan G, Zhu Z, Jing J, Lv L, Lou Z, et al. (2011) Characterization of constituents in Sini decoction and rat plasma by high-performance liquid chromatography with diode array detection coupled to time-of-flight mass spectrometry. Biomed Chromatogr 25: 913-924.
46. Sangster T, Major H, Plumb R, Wilson AJ, Wilson ID, (2006) A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst 131: 1075-1078.
47. Gika HG, Theodoridis GA, Wingate JE, Wilson ID, (2007) Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res 6: 3291-3303.
48. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G, (2006) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78: 779-787.
49. Smilde AK, van der Werf MJ, Bijlsma S, van der Werff-van der Vat BJ, Jellema RH, (2005) Fusion of mass spectrometry-based metabolomics data. Anal Chem 77: 6729-6736.